Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II/III seamless randomized double-blind placebo-controlled outpatient trial of BI 767551 in mild to moderate COVID-19
2020-005588-29Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Mar 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing BI 767551 with Placebo (2 arms). Primary endpoint: Phase II primary endpoint. Started Mar 2021; status: terminated.
02
Drugs
lomtegovimab
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2020-005588-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-005588-29.